OpenNashPodcasts

Topic

insitro

Insitro is a company led by Daphne Koller that applies AI to drug design and human biology, and the podcasts here cover how it started, how it works and what drugs it is developing. Koller told Luke Timmerman that insitro was founded in 2018, and she explained to NEJM AI Grand Rounds that the name joins "in silico" (computer) and "in vitro" (lab).

The conversations also cover insitro's partners, including Gilead Sciences, Eli Lilly and Bristol Myers Squibb, and its work on liver disease, ALS and eye disease. Koller told Timmerman that three programs are expected to enter the clinic within about 18 months. She also described how agentic AI systems shortened its experiment cycles from six to nine months to about eight weeks.

40 facts from 6 episodes, in date order. These are what speakers said on the shows, each linked to the moment it was said. They aren't independently verified.

2018

Jim Tannenbaum of Foresight Capital was insitro's first investor, followed soon by Krishna Yeshwant of GV and Bob Nelson of Arch Venture Partners.

“So the first investor was Jim Tannenbaum. And then very soon thereafter, Krishna Yeshwant from GV and Bob Nelson from Arch.”

Daphne Koller · Ep79: Daphne Koller on Machine Learning for Drug Discovery, 0:37:53

2018

Insitro was founded in 2018 and has raised $750 million from venture capital and pharma partnerships.

“Insitro was founded in 2018 and has secured $750 million in funding from venture capital firms and through partnerships with big drug makers”

Luke Timmerman · Ep213: Daphne Koller on The Moment in AI Drug Discovery, 0:00:01

2020

insitro raised a $143 million Series B financing in May 2020, led by Andreessen Horowitz.

“as it raised a $143 million Series B financing in May 2020, led by Andreessen Horowitz, and which included earlier investors like ArchVenture Partners, Foresight Capital, GV, and Third Rock Ventures.”

Luke Timmerman · Ep79: Daphne Koller on Machine Learning for Drug Discovery, 0:00:41

2026

Daphne Koller said insitro's first drug, for the fatty liver disease MASH, would enter the clinic the year after the panel.

“Our first drug is heading into the clinic next year. Um, it's in the disease called MASH, which is a terrible fatty liver disease.”

Guest · AI’s journey from the lab to the marketplace, 0:18:32

Undated

Daphne Koller says many insitro hires are roughly 70 percent life scientists who can program in Python, an approach she calls recruiting 'damp' scientists.

“They are 70 % life scientists, but they know how to program in Python and analyze their own data.”

Daphne Koller · Ep79: Daphne Koller on Machine Learning for Drug Discovery, 0:47:12

Undated

insitro makes induced pluripotent stem cells from donors' cells and differentiates them into cell types such as neurons or liver cells for experiments.

“where we can take cells from you or me, convert them into pluripotent status. stem cells and then differentiate them into a Daphne neuron or a Daphne hepatocyte or any one of the set of lineages that the community has developed differentiation protocols for.”

Daphne Koller · Ep79: Daphne Koller on Machine Learning for Drug Discovery, 0:52:38

Undated

Daphne Koller says insitro relies heavily on unsupervised and self-supervised learning because there are too few successful drugs to use as training examples.

“We also have a much greater reliance on unsupervised and self-supervised machine learning algorithms where the need for supervised examples is much, much lower.”

Daphne Koller · From Theory to Therapy: The Evolution of AI in Medicine with Dr. Daphne Koller, 0:40:44

Undated

Daphne Koller says Eli Lilly makes a particular type of molecule for insitro because Lilly has capacity and capabilities insitro lacks.

“We have actually an kind of inverse collaboration with Lilly where they have extra capacity and capabilities in making a particular type of molecules that isn't within our sweet spot, and they're making that for us.”

Daphne Koller · The Machine Learns Medicine: Daphne Koller’s Vision for AI in Biotech, 0:29:42

Undated

Daphne Koller said competitors in physical AI have no shortcuts and must build custom hardware, data and models, which she described as a competitive moat.

“You have to build the custom hardware, you have to collect the custom data, you have to build the custom models that understand the physical world and causality.”

Guest · AI’s journey from the lab to the marketplace, 0:17:40

Undated

Insitro partners with Moorfields Hospital in the UK, which holds one of the world's largest collections of OCT eye scan data.

“our partnership with the Moorfields Hospital in the UK that has one of the world's largest collections of OCT data, which is a form of eye scans.”

Daphne Koller · Ep213: Daphne Koller on The Moment in AI Drug Discovery, 0:22:58

Undated

Insitro's partnership with Eli Lilly produced models predicting in vivo pharmacokinetic properties of small molecules.

“our really exciting partnership with Lilly that allowed us to predict in vivo pharmacokinetic properties for small molecules.”

Daphne Koller · Ep213: Daphne Koller on The Moment in AI Drug Discovery, 0:23:55

Undated

Koller says agentic LLM systems cut Insitro's experimental design and execution from six to nine months to about eight weeks.

“took a process that used to take our scientists like six to nine months and shrunk it down to, you know, eight weeks.”

Daphne Koller · Ep213: Daphne Koller on The Moment in AI Drug Discovery, 0:26:46

Undated

Insitro's MASH drug is a liver-targeted siRNA, designed because inhibiting IRS-1 throughout the body would be harmful.

“A liver-targeted siRNA, which is actually really critical because you would not want to inhibit IRS-1 systemically.”

Daphne Koller · Ep213: Daphne Koller on The Moment in AI Drug Discovery, 0:32:09

Undated

Insitro disclosed IRS-1 because its patent on the oligonucleotide sequence revealed the target.

“We filed a patent in order to protect the composition of matter, And for an oligo therapeutic, the sequence that you are disclosing in the patent tells you the target.”

Daphne Koller · Ep213: Daphne Koller on The Moment in AI Drug Discovery, 0:33:04

Undated

Koller says Insitro has found three ALS programs aimed at the roughly 97 percent of patients with TDP-43 pathology.

“we have been, we believe, able to find not one but three programs that truly are disease-modifying in the 97 % of ALS patients that have what is called TDP-43 pathology”

Daphne Koller · Ep213: Daphne Koller on The Moment in AI Drug Discovery, 0:21:20

Undated

Bristol Myers Squibb chose to pursue the first ALS target as a small molecule, while Insitro advances it as an intrathecal oligonucleotide at its own cost.

“BMS elected to pursue the first of those targets, ALS-1, as a small molecule.”

Daphne Koller · Ep213: Daphne Koller on The Moment in AI Drug Discovery, 0:47:07

Episodes